Clinical studies found that nuclear AR-V7+ patients do not benefit from AR-targeted therapies1-3
AR-V7+ patients treated with AR-targeted therapies had significantly reduced overall survival1*
Study Details: Memorial Sloan Kettering Cancer Center Study #1
A study published in JAMA Oncology from Memorial Sloan Kettering Cancer Center demonstrated that mCRPC patients with AR-V7+ circulating tumor cells (CTCs) experience faster progression and lower median overall survival when compared to mCRPC patients with AR-V7- CTCs.*
* The presence of AR-V7 protein in the nucleus signals resistance to continued AR-targeted therapies and is associated with rapid disease progression and shorter cancer-specific survival. This suggests that patients with detectable blood levels of AR-V7 should consider life-prolonging chemotherapy as an alternative to potentially less effective and more expensive hormonal treatment with AR-targeted therapies.
Study Details: Memorial Sloan Kettering Cancer Center Study #3
A 2016 study published in European Urology analyzed outcomes for patients with mCRPC on AR-targeted therapies and standard chemotherapy. The investigators found that patients who had nuclear AR-V7+ CTCs were likely to survive longer on taxane-based chemotherapy, whereas location-agnostic AR-V7 expression (AR-V7 present in either nucleus, cytoplasm, or both) was less prognostic and not predictive of treatment response.
AR-V7-estrogen receptor splice variant 7
Slide 18 et al. Eur Urol 2017.